Toll Free: 1-888-928-9744

Pozen, Inc. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 36 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Pozen, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Pozen, Inc. - Product Pipeline Review - 2014', provides an overview of the Pozen, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pozen, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Pozen, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Pozen, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Pozen, Inc.'s pipeline products

Reasons to buy

- Evaluate Pozen, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Pozen, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Pozen, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Pozen, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pozen, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Pozen, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Pozen, Inc. Snapshot 5
Pozen, Inc. Overview 5
Key Information 5
Key Facts 5
Pozen, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Pozen, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Pozen, Inc. - Pipeline Products Glance 11
Pozen, Inc. - Late Stage Pipeline Products 11
Filing rejected/Withdrawn Products/Combination Treatment Modalities 11
Phase III Products/Combination Treatment Modalities 12
Pozen, Inc. - Clinical Stage Pipeline Products 13
Phase I Products/Combination Treatment Modalities 13
Pozen, Inc. - Drug Profiles 14
(aspirin EC + omeprazole IR) 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
(enteric coated aspirin + immediate release omeprazole) 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
(sumatriptan succinate + naproxen sodium) 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
(aspirin + omeprazole) 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
PA-65020 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Pozen, Inc. - Pipeline Analysis 21
Pozen, Inc. - Pipeline Products by Target 21
Pozen, Inc. - Pipeline Products by Route of Administration 22
Pozen, Inc. - Pipeline Products by Molecule Type 23
Pozen, Inc. - Pipeline Products by Mechanism of Action 24
Pozen, Inc. - Recent Pipeline Updates 25
Pozen, Inc. - Dormant Projects 31
Pozen, Inc. - Company Statement 32
Pozen, Inc. - Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36
List of Tables
Pozen, Inc., Key Information 5
Pozen, Inc., Key Facts 5
Pozen, Inc. - Pipeline by Indication, 2014 7
Pozen, Inc. - Pipeline by Stage of Development, 2014 8
Pozen, Inc. - Monotherapy Products in Pipeline, 2014 9
Pozen, Inc. - Combination Treatment Modalities in Pipeline, 2014 10
Pozen, Inc. - Filing rejected/Withdrawn, 2014 11
Pozen, Inc. - Phase III, 2014 12
Pozen, Inc. - Phase I, 2014 13
Pozen, Inc. - Pipeline by Target, 2014 21
Pozen, Inc. - Pipeline by Route of Administration, 2014 22
Pozen, Inc. - Pipeline by Molecule Type, 2014 23
Pozen, Inc. - Pipeline Products by Mechanism of Action, 2014 24
Pozen, Inc. - Recent Pipeline Updates, 2014 25
Pozen, Inc. - Dormant Developmental Projects,2014 31
Pozen, Inc., Subsidiaries 34 



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify